Vaxart (VXRT) Gets a Buy Rating from H.C. Wainwright


H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Vaxart (VXRT) today and set a price target of $17.00. The company’s shares closed last Monday at $5.57.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.4% and a 36.2% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Aridis Pharmaceuticals, and Achieve Life Sciences.

Vaxart has an analyst consensus of Strong Buy, with a price target consensus of $19.67, implying a 304.3% upside from current levels. In a report issued on November 12, B.Riley Financial also reiterated a Buy rating on the stock with a price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.49 and a one-year low of $0.27. Currently, Vaxart has an average volume of 17.6M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Biota Holdings Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.

Read More on VXRT:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts